Partial replicate designs [RSABE / ABEL]

posted by The Outlaw Torn – Europe, 2013-09-25 10:21 (4660 d 21:17 ago) – Posting: # 11556
Views: 7,799

Good morning Europe (and hello to the rest of you),

I'd like to get you folks' take on something and some informtion on the other.

Thing one (not-so-subtle Dr. Seuss reference! and yes, you guessed it, I have young children). :sleeping: Okay, what is the advantage of conducting a full replicate BE study on an suspected HVDP if the ability to widen CIs is based solely on the reference product variability (basically, it's cheaper to conduct a partial with RTR/RRT, right?)?

The second thing is the following. What is the sample size estimate for a drug (not Schützomycin) with a intra-subject variability of 37.5%? And how would those subjects be distributed per group in said partial replicate?

Just in case ya'll are wondering. I'm actually not asking ya'll to do my work for me, I'm trying to wrap my head around a concept I don't seem to be able to wrap my head around when I should.

Thank you,
Outlaw Torn

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
280 visitors (0 registered, 280 guests [including 38 identified bots]).
Forum time: 07:39 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5